X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-10-03 | ACLX | Arcellx, Inc. | Gilson Michelle | CFO | S - Sale | $86.04 | -5,946 | 13,830 | -30% | -$511,603 | |||||
2025-10-06 | FENC | Fennec Pharmaceuticals Inc. | Raykov Rosty | Dir | S - Sale | $9.78 | -10,000 | 82,501 | -11% | -$97,800 | ||||||
2025-10-02 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $29.16 | -124 | 102,586 | 0% | -$3,616 | ||||||
2025-10-02 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $29.16 | -140 | 124,402 | 0% | -$4,083 | ||||||
| D | 2025-10-02 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $29.16 | -476 | 632,560 | 0% | -$13,881 | |||||
2025-10-02 | TWST | Twist Bioscience Corp | Finn Patrick John | Pres, COO | S - Sale | $29.16 | -206 | 232,482 | 0% | -$6,007 | ||||||
| M | 2025-10-01 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $39.43 | -41,752 | 1,597,308 | -3% | -$1,646,237 | |||||
| D | 2025-10-01 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale+OE | $39.80 | -5,110 | 284,733 | -2% | -$203,378 | |||||
| DM | 2025-10-01 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $71.86 | -60,000 | 733,719 | -8% | -$4,311,745 | |||||
2025-10-01 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | See remarks | S - Sale | $15.00 | -5,609 | 5,503 | -50% | -$84,135 | ||||||
| D | 2025-08-08 | ASMB | Assembly Biosciences, Inc. | Gilead Sciences, Inc. | 10% | P - Purchase | $0.00 | +2,295,920 | 4,505,391 | +104% | +$0 | |||||
2025-10-01 | BEAM | Beam Therapeutics Inc. | Cavanagh Bethany J | SVP, Finance, Treasurer | S - Sale | $24.53 | -467 | 44,045 | -1% | -$11,456 | ||||||
2025-10-01 | BEAM | Beam Therapeutics Inc. | Bellon Christine | GC | S - Sale | $24.53 | -373 | 116,921 | 0% | -$9,150 | ||||||
| DM | 2025-10-01 | BEAM | Beam Therapeutics Inc. | Evans John M. | CEO | S - Sale+OE | $24.57 | -50,000 | 1,089,667 | -4% | -$1,228,323 | |||||
2025-09-30 | ZIVO | Zivo Bioscience, Inc. | Yaldoo Laith L | Dir, 10% | P - Purchase | $15.99 | +15,322 | 573,436 | +3% | +$244,999 | ||||||
2025-09-30 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $46.01 | -224,974 | 2,656,888 | -8% | -$10,352,017 | ||||||
| D | 2025-09-30 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $35.23 | -61,849 | 0 | -100% | -$2,178,940 | |||||
2025-10-01 | VIR | Vir Biotechnology, Inc. | Sato Vicki L | Dir | S - Sale | $5.84 | -22,000 | 1,232,391 | -2% | -$128,396 | ||||||
2025-10-01 | HALO | Halozyme Therapeutics, Inc. | Connaughton Bernadette | Dir | S - Sale | $75.24 | -2,000 | 44,952 | -4% | -$150,481 | ||||||
| D | 2025-09-30 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $40.09 | -5,000 | 0 | -100% | -$200,450 | |||||
2025-09-29 | RGNX | Regenxbio Inc. | Simpson Curran | CEO | S - Sale | $10.03 | -7,624 | 236,973 | -3% | -$76,469 | ||||||
2025-09-30 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $81.28 | -21,034 | 624 | -97% | -$1,709,723 | ||||||
2025-09-29 | GILD | Gilead Sciences, Inc. | O'Day Daniel Patrick | COB, CEO | S - Sale | $111.66 | -10,000 | 591,203 | -2% | -$1,116,564 | ||||||
| D | 2025-09-29 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $39.19 | -12,755 | 0 | -100% | -$499,868 | |||||
2025-09-26 | DTIL | Precision Biosciences Inc | Frankel Stanley | Dir | P - Purchase | $4.97 | +2,700 | 16,778 | +19% | +$13,419 | ||||||
2025-09-29 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $80.16 | -73 | 21,658 | 0% | -$5,852 | ||||||
2025-09-23 | FDMT | 4D Molecular Therapeutics, Inc. | Bizily Scott | GC | S - Sale | $8.00 | -2,407 | 7,596 | -24% | -$19,256 | ||||||
2025-09-26 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $80.12 | -12,396 | 21,731 | -36% | -$993,155 | ||||||
| D | 2025-09-25 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.76 | -100,000 | 954,229 | -9% | -$476,000 | |||||
2025-09-24 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $44.26 | -1,799 | 50,425 | -3% | -$79,624 | ||||||
2025-09-24 | TARS | Tarsus Pharmaceuticals, Inc. | Azamian Bobak R. | Pres, CEO, Board Chair | S - Sale | $55.37 | -6,000 | 865,741 | -1% | -$332,220 | ||||||
2025-09-23 | SMNR | Semnur Pharmaceuticals, Inc. | Scilex Holding Co | 10% | S - Sale | $16.00 | -12,500,000 | 188,554,849 | -6% | -$200,000,000 | ||||||
2025-09-22 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $30.67 | -3,353 | 108,964 | -3% | -$102,846 | ||||||
2025-09-22 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $27.56 | -233 | 102,710 | 0% | -$6,421 | ||||||
2025-09-22 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $27.56 | -295 | 124,542 | 0% | -$8,130 | ||||||
| D | 2025-09-22 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $27.56 | -1,704 | 633,036 | 0% | -$46,962 | |||||
| D | 2025-09-22 | JSPR | Jasper Therapeutics, Inc. | Wiggans Thomas G | Dir | P - Purchase | $2.43 | +41,000 | 46,000 | +820% | +$99,630 | |||||
| D | 2025-09-22 | JSPR | Jasper Therapeutics, Inc. | Lucas Svetlana | Dir | P - Purchase | $2.43 | +20,000 | 20,000 | New | +$48,600 | |||||
| D | 2025-09-22 | JSPR | Jasper Therapeutics, Inc. | Martell Ron | Pres, CEO | P - Purchase | $2.43 | +41,000 | 74,118 | +124% | +$99,630 | |||||
| D | 2025-09-22 | JSPR | Jasper Therapeutics, Inc. | Shizuru Judith Anne | Dir | P - Purchase | $2.43 | +41,000 | 156,901 | +35% | +$99,630 | |||||
2025-09-22 | DTIL | Precision Biosciences Inc | Brown Melinda | Dir | P - Purchase | $4.89 | +1,400 | 21,965 | +7% | +$6,846 | ||||||
2025-09-22 | HALO | Halozyme Therapeutics, Inc. | Labrosse Nicole | SVP, CFO | S - Sale | $77.95 | -2,227 | 22,079 | -9% | -$173,584 | ||||||
| D | 2025-09-19 | BCDA | Biocardia, Inc. | Stertzer Simon H | Dir | P - Purchase | $1.25 | +398,400 | 714,275 | +126% | +$498,000 | |||||
| D | 2025-09-19 | BCDA | Biocardia, Inc. | Blank Andrew Scott | Dir | P - Purchase | $1.25 | +288,000 | 636,058 | +83% | +$360,000 | |||||
| D | 2025-09-19 | BCDA | Biocardia, Inc. | Altman Peter | Pres, CEO | P - Purchase | $1.25 | +48,000 | 216,762 | +28% | +$60,000 | |||||
2025-09-18 | LENZ | Lenz Therapeutics, Inc. | Versant Venture Capital Vi, L.P. | 10% | S - Sale | $42.23 | -135,304 | 2,881,862 | -4% | -$5,714,356 | ||||||
| DM | 2025-09-18 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $39.01 | -22,686 | 0 | -100% | -$884,909 | |||||
| M | 2025-09-18 | ACLX | Arcellx, Inc. | Heery Christopher | CHIEF MEDICAL OFFICER | S - Sale | $80.01 | -3,643 | 34,127 | -10% | -$291,468 | |||||
2025-09-16 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $1.54 | -447,278 | 32,781,209 | -1% | -$688,853 | ||||||
2025-09-16 | RVMD | Revolution Medicines, Inc. | Wei Lin | Chief Medical Officer | S - Sale | $45.82 | -2,160 | 88,339 | -2% | -$98,982 | ||||||
2025-09-16 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale | $45.82 | -5,367 | 284,047 | -2% | -$245,942 | ||||||
2025-09-16 | RVMD | Revolution Medicines, Inc. | Goldsmith Mark A | See Remarks | S - Sale | $45.82 | -13,411 | 958,761 | -1% | -$614,558 | ||||||
2025-09-16 | RVMD | Revolution Medicines, Inc. | Horn Margaret A | COO | S - Sale | $45.82 | -4,775 | 145,900 | -3% | -$218,814 | ||||||
2025-09-16 | RVMD | Revolution Medicines, Inc. | Cislini Jeff | GC | S - Sale | $45.82 | -1,869 | 52,224 | -3% | -$85,647 | ||||||
2025-09-16 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale | $45.82 | -2,320 | 110,994 | -2% | -$106,314 | ||||||
| D | 2025-09-17 | KYMR | Kymera Therapeutics, Inc. | Jacobs Bruce N. | CFO | S - Sale+OE | $50.00 | -79,220 | 227,409 | -26% | -$3,961,380 | |||||
2025-09-16 | SRRK | Scholar Rock Holding Corp | Peng Katie | Dir | S - Sale | $32.53 | -1,006 | 33,914 | -3% | -$32,726 | ||||||
2025-09-16 | SRRK | Scholar Rock Holding Corp | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | S - Sale | $33.52 | -3,178 | 112,317 | -3% | -$106,527 | ||||||
2025-09-15 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $25.33 | -94 | 102,943 | 0% | -$2,381 | ||||||
| D | 2025-09-15 | ADMA | Adma Biologics, Inc. | Grossman Adam S | Pres, CEO | S - Sale+OE | $16.13 | -21,000 | 3,750,233 | -1% | -$338,730 | |||||
2025-09-15 | GILD | Gilead Sciences, Inc. | Mercier Johanna | Chief Commercial Officer | S - Sale | $113.57 | -3,000 | 113,193 | -3% | -$340,710 | ||||||
2025-09-15 | GILD | Gilead Sciences, Inc. | Dickinson Andrew D | CFO | S - Sale | $113.57 | -2,500 | 159,555 | -2% | -$283,925 | ||||||
2025-09-15 | MAZE | Maze Therapeutics, Inc. | Scheller Richard H | Dir | S - Sale | $22.37 | -20,744 | 0 | -100% | -$464,035 | ||||||
| DM | 2025-09-12 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $35.66 | -22,732 | 0 | -100% | -$810,701 | |||||
| D | 2025-09-15 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $35.10 | -1,000 | 0 | -100% | -$35,100 | |||||
| D | 2025-09-16 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $49.00 | -30,000 | 660,482 | -4% | -$1,470,000 | |||||
| DM | 2025-09-11 | RVMD | Revolution Medicines, Inc. | Kelsey Stephen Michael | See Remarks | S - Sale+OE | $44.46 | -125,000 | 289,414 | -30% | -$5,557,754 | |||||
| M | 2025-09-11 | PASG | Passage Bio, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $6.99 | +32,008 | 1,215,725 | +3% | +$223,735 | |||||
2025-09-11 | CDTX | Cidara Therapeutics, Inc. | Davarpanah Nicole Negar | Chief Medical Officer | S - Sale | $62.86 | -474 | 31,418 | -1% | -$29,797 | ||||||
| M | 2025-09-11 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $1.73 | -984,805 | 33,228,487 | -3% | -$1,703,971 | |||||
2025-09-11 | CGON | Cg Oncology, Inc. | Liu Brian Guan-Chyun | Dir | P - Purchase | $33.00 | +1,515,151 | 1,515,151 | New | +$49,999,983 | ||||||
| D | 2025-09-10 | TIL | Instil Bio, Inc. | Laumas Sandeep | CFO, CBO | S - Sale+OE | $23.39 | -30,000 | 0 | -100% | -$701,667 | |||||
2025-09-10 | RGNX | Regenxbio Inc. | Simpson Curran | CEO | S - Sale | $10.02 | -7,734 | 244,597 | -3% | -$77,495 | ||||||
| D | 2025-09-10 | RXRX | Recursion Pharmaceuticals, Inc. | Gibson Christopher | CEO | S - Sale+OE | $4.71 | -100,000 | 954,229 | -9% | -$471,000 | |||||
| D | 2025-09-10 | TSHA | Taysha Gene Therapies, Inc. | Nagendran Sukumar | Pres, Head of R, D | S - Sale+OE | $3.23 | -200,000 | 1,006,439 | -17% | -$646,000 | |||||
| DM | 2025-09-10 | IMCR | Immunocore Holdings Plc | Berman David M | HEAD OF R, D | S - Sale+OE | $36.20 | -50,419 | 0 | -100% | -$1,824,967 | |||||
| D | 2025-09-10 | HALO | Halozyme Therapeutics, Inc. | Labrosse Nicole | SVP, CFO | S - Sale+OE | $75.71 | -20,000 | 24,306 | -45% | -$1,514,267 | |||||
| D | 2025-09-10 | RGEN | Repligen Corp | Hunt Anthony | Dir | S - Sale+OE | $120.52 | -29,111 | 100,743 | -22% | -$3,508,389 | |||||
| M | 2025-09-08 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $1.95 | -1,263,647 | 34,213,292 | -4% | -$2,457,975 | |||||
2025-09-08 | IPSC | Century Therapeutics, Inc. | Carr Douglas | SVP Finance, Operations | S - Sale | $0.50 | -263 | 405,423 | 0% | -$132 | ||||||
2025-09-08 | IPSC | Century Therapeutics, Inc. | Pfeiffenberger Brent | Pres, CEO | S - Sale | $0.50 | -488 | 3,268,909 | 0% | -$244 | ||||||
2025-09-08 | IPSC | Century Therapeutics, Inc. | Russotti Gregory | See Remarks | S - Sale | $0.50 | -539 | 484,281 | 0% | -$270 | ||||||
2025-09-08 | TARS | Tarsus Pharmaceuticals, Inc. | Link William J Phd | Dir | S - Sale | $57.00 | -27,116 | 153,778 | -15% | -$1,545,612 | ||||||
| A | 2025-08-18 | LXEO | Lexeo Therapeutics, Inc. | Townsend Richard Nolan | CEO | S - Sale | $4.67 | -1,115 | 220,058 | -1% | -$5,205 | |||||
| M | 2025-09-08 | DNA | Ginkgo Bioworks Holdings, Inc. | Henry Christian O | Dir | S - Sale | $10.99 | -20,000 | 24,310 | -45% | -$219,800 | |||||
2025-09-08 | TWST | Twist Bioscience Corp | Cho Dennis | See Remarks | S - Sale | $25.76 | -269 | 103,037 | 0% | -$6,929 | ||||||
2025-09-08 | TWST | Twist Bioscience Corp | Green Paula | SVP of HR | S - Sale | $25.76 | -892 | 124,837 | -1% | -$22,978 | ||||||
| D | 2025-09-08 | TWST | Twist Bioscience Corp | Leproust Emily M. | CEO | S - Sale+OE | $25.76 | -2,265 | 634,740 | 0% | -$58,346 | |||||
2025-09-08 | TWST | Twist Bioscience Corp | Werner Robert F. | Chief Accounting Officer | S - Sale | $25.76 | -235 | 48,454 | 0% | -$6,054 | ||||||
| D | 2025-09-05 | CGON | Cg Oncology, Inc. | Mulay James | Dir | S - Sale+OE | $31.53 | -27,015 | 0 | -100% | -$851,797 | |||||
2025-09-03 | APGE | Apogee Therapeutics, Inc. | Dambkowski Carl | Chief Medical Officer | S - Sale | $37.87 | -2,725 | 233,548 | -1% | -$103,198 | ||||||
| M | 2025-09-03 | VOR | Vor Biopharma Inc. | Reprogrammed Interchange LLC | 10% | S - Sale | $1.97 | -1,407,628 | 35,476,939 | -4% | -$2,767,982 | |||||
| DM | 2025-09-02 | RVMD | Revolution Medicines, Inc. | Anders Jack | CFO | S - Sale+OE | $40.10 | -10,000 | 113,314 | -8% | -$400,992 | |||||
| DM | 2025-09-02 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $74.08 | -60,000 | 733,719 | -8% | -$4,444,626 | |||||
2025-09-03 | CGON | Cg Oncology, Inc. | Song Hong Fang | Dir | S - Sale | $27.80 | -100,000 | 7,039,077 | -1% | -$2,779,542 | ||||||
2025-09-02 | ALEC | Alector, Inc. | Wong-Sarad Grace | Principal Accounting Officer | S - Sale | $2.50 | -5,910 | 103,448 | -5% | -$14,756 | ||||||
2025-09-02 | ALEC | Alector, Inc. | Berkley Neil Lindsay | Principal Financial Officer | S - Sale | $2.50 | -15,842 | 346,570 | -4% | -$39,554 | ||||||
| D | 2025-09-03 | CGON | Cg Oncology, Inc. | Post Leonard E | Dir | S - Sale+OE | $28.00 | -1,000 | 0 | -100% | -$28,000 | |||||
2025-09-02 | ALEC | Alector, Inc. | Kenkare-Mitra Sara | Pres, Head of R, D | S - Sale | $2.50 | -23,638 | 543,339 | -4% | -$59,019 | ||||||
2025-09-02 | ALEC | Alector, Inc. | Rosenthal Arnon | CEO | S - Sale | $2.50 | -51,562 | 6,280,595 | -1% | -$128,740 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |